Predictive Oncology Inc. (POAI)
- Previous Close
1.6500 - Open
1.5500 - Bid 1.6000 x 100
- Ask 1.7200 x 100
- Day's Range
1.5000 - 1.5700 - 52 Week Range
1.1200 - 7.1200 - Volume
113,969 - Avg. Volume
155,900 - Market Cap (intraday)
6.176M - Beta (5Y Monthly) 1.29
- PE Ratio (TTM)
-- - EPS (TTM)
-3.4800 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Predictive Oncology Inc., a science-driven company that applies artificial intelligence to support the discovery and development of optimal cancer therapies. It operates through three segments: Pittsburgh, Birmingham, and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of approximately 150,000 tumor samples and creates proprietary 3D culture models used in drug development. The Birmingham segment offers contract services and research focused on solubility improvements, stability studies, and protein production. The Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Pittsburgh, Pennsylvania.
www.predictive-oncology.comRecent News: POAI
Performance Overview: POAI
Trailing total returns as of 5/2/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: POAI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: POAI
Valuation Measures
Market Cap
6.70M
Enterprise Value
832.65k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.72
Price/Book (mrq)
0.81
Enterprise Value/Revenue
0.47
Enterprise Value/EBITDA
-0.06
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-43.34%
Return on Equity (ttm)
-93.11%
Revenue (ttm)
1.78M
Net Income Avi to Common (ttm)
-13.98M
Diluted EPS (ttm)
-3.4800
Balance Sheet and Cash Flow
Total Cash (mrq)
8.73M
Total Debt/Equity (mrq)
34.54%
Levered Free Cash Flow (ttm)
-8.53M